Please login to the form below

Not currently logged in
Email:
Password:

UCB admits Keppra misbranding offence

UCB is to pay $34m after admitting to off-label marketing of its epilepsy drug Keppra as a treatment for migraine

UCB has agreed to pay $34.4m to settle a dispute with the US Department of Justice regarding off-label marketing of its epilepsy drug Keppra.

The Belgian company's US subsidiary pleaded guilty to a single misdemeanour violation and entered into a separate civil settlement agreement to resolve allegations relating to misbranding of Keppra (levetiracetam) as a migraine treatment.

Greg Duncan, UCB's president for North American operations, said: "We have worked diligently over the years to enhance our compliance programme and we continue to evolve our compliance efforts to meet the changing demands of the regulatory environment in which we operate. We are pleased to have resolved this matter."

The events occurred more than six years ago, and UCB said it cooperated fully with the US authorities since learning of the investigation in 2008. It also signed a five-year corporate integrity agreement with the US Department of Health and Human Services.

13th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...
MIT reveals new pill to deliver insulin
A new MIT research project, sponsored by Novo Nordisk, is aiming to deliver insulin orally with a pill that releases medicine in the stomach lining. Dina Patel interviews the team...
Fearless Girl cover
25 Women Leaders in UK Healthcare
Women trailblazers helping to shape the future of healthcare (Part 1)...

Infographics